Yu W N, Pan S Y, Wang C, Huang Z D, Wang X L, Zhu S, Ding Y, Wang X L
Department of Gynecology, Jiangsu Province Hospital, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Department of Pathology, Jiangsu Province Hospital, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Zhonghua Fu Chan Ke Za Zhi. 2025 Jun 25;60(6):450-460. doi: 10.3760/cma.j.cn112141-20250205-00040.
To explore the clinicopathological characteristics and prognosis of fumarate hydratase-deficient uterine leiomyoma (FH-dUL). Clinical data and follow-up information for 117 patients with FH-dUL diagnosed through surgical pathology and immunohistochemistry in the First Affiliated Hospital of Nanjing Medical University from January 2020 to December 2024, were collected. A control group of 130 patients with common uterine leiomyomas was also included. The differences between the two groups in clinical, imaging, and pathological characteristics were compared. Additionally, recurrence rates, fertility outcomes for FH-dUL patients, and the incidence of renal cancer in FH germline mutation carriers were monitored. (1) Comparison of clinicopathological characteristics: the median age of 117 FH-dUL patients was 35 years, and the median age at first diagnosis of uterine leiomyomas was 29 years, both significantly younger than the control group (41 and 36 years; both <0.01). The FH-dUL group showed significantly higher incidences of uterine myomectomy, multiple leiomyomas, diffusion restriction on pelvic magnetic resonance imaging diffusion weighted imaging, and typical pathological features (candelabra-like vessels, bizarre nuclei, cytoplasmic eosinophilic globules, perinuclear halo, cellular atypia) and higher ultrasound blood flow score (all <0.05). Of the 30 FH-dUL patients who underwent genetic testing, 9 had germline mutations, 3 had somatic mutations, and 6 had mutations of unclear origin. Among the 9 FH gene germline mutation patients, 2 had already developed renal cell carcinoma. (2) Recurrence analysis: among the 56 patients who underwent uterine myomectomy, 22 (39.3%, 22/56) experienced recurrence during follow-up, compared to 12 (21.8%, 12/55) of the 55 patients in the control group, the difference between the two groups was statistically significant (=0.046). Multivariate binary logistic regression analysis showed that cellular leiomyomas (=9.489, 95%: 1.740-51.755; =0.009) and multiple uterine leiomyomas (=10.709, 95%: 1.354-84.683; =0.025) were significant risk factors for recurrence in FH-dUL. (3) Fertility analysis: among the 66 FH-dUL patients who underwent fertility-preserving surgery, 16 had the intention to have fertility desire, only 2 (2/16) completed their fertility plans during follow-up. Clinicopathological features and imaging features help to differentiate FH-dUL from common type uterine fibroids, but lack specificity, and the diagnosis of FH-dUL is based on immunohistochemistry. The recurrence rate after resection of FH-dUL is high, and cellular and multiple leiomyomas are important predictors of recurrence. It is crucial to perform genetic testing, genetic counseling, drug treatment to prevent recurrence, fertility guidance, and long-term comprehensive management after surgery for FH-dUL management.
探讨富马酸水合酶缺陷型子宫平滑肌瘤(FH-dUL)的临床病理特征及预后。收集2020年1月至2024年12月在南京医科大学第一附属医院经手术病理及免疫组化确诊的117例FH-dUL患者的临床资料及随访信息。同时纳入130例普通子宫平滑肌瘤患者作为对照组。比较两组在临床、影像及病理特征方面的差异。此外,监测FH-dUL患者的复发率、生育结局以及FH基因种系突变携带者的肾癌发病率。(1)临床病理特征比较:117例FH-dUL患者的中位年龄为35岁,子宫平滑肌瘤首次诊断时的中位年龄为29岁,均显著低于对照组(分别为41岁和36岁;均P<0.01)。FH-dUL组子宫肌壁间肌瘤、多发平滑肌瘤、盆腔磁共振成像扩散加权成像上的扩散受限及典型病理特征(树枝状血管、奇异核、胞质嗜酸性小球、核周晕、细胞异型性)的发生率显著更高,超声血流评分也更高(均P<0.05)。在30例行基因检测的FH-dUL患者中,9例有生殖系突变,3例有体细胞突变,6例突变来源不明。在9例FH基因生殖系突变患者中,2例已发生肾细胞癌。(2)复发分析:在56例行子宫肌壁间肌瘤切除术的患者中,22例(39.3%,22/56)在随访期间复发,而对照组55例患者中有12例(21.8%,12/55)复发,两组差异有统计学意义(P=0.046)。多因素二元逻辑回归分析显示,细胞性平滑肌瘤(P=9.489,95%CI:1.740-51.755;P=0.009)和多发子宫平滑肌瘤(P=10.709,95%CI:1.354-84.683;P=0.025)是FH-dUL复发的重要危险因素。(3)生育分析:在66例行保留生育功能手术的FH-dUL患者中,16例有生育意愿,随访期间仅2例(2/16)完成生育计划。临床病理特征和影像特征有助于FH-dUL与普通型子宫平滑肌瘤相鉴别,但缺乏特异性,FH-dUL的诊断基于免疫组化。FH-dUL切除术后复发率高,细胞性和多发性平滑肌瘤是复发的重要预测因素。对FH-dUL进行管理时,进行基因检测、遗传咨询、药物预防复发治疗、生育指导及术后长期综合管理至关重要。